Jan 9
12:00 pm | Webinar

Journal Club: Factors affecting patient-reported outcomes after red blood cell transfusion in medical patients

Speaker Matthew Yan, MD Transfusion Medicine Physician Trainee University of Toronto Objectives Review the concept of patient-reported outcomes in medicine Discuss the utilization of patient-reported outcomes in transfusion Critically review and appraise the article: Factors affecting patient

Jun 13
12:00 pm | Toronto/Webinar

Journal Club: Emergency transfusion of patients with unknown blood type with blood group O Rhesus D positive red blood cell concentrates

Speaker Shadhiya Al Khan, MD Transfusion Medicine Fellow Canadian Blood Services University of British Columbia Objectives Become aware of outcome of a transfusion policy of transfusing all emergency patients with unknown blood type with O RhD+ PRBCs. Anti D alloimmunization rates in different RhD

Sep 13
12:00 pm | Toronto/Webinar

Journal Club: The Impact of Donor Characteristics on Patient Outcomes

Speaker(s): Dr. Matthew Yan Transfusion Medicine Physician Trainee University of Toronto Event objective(s): Review the literature on donor attributes and associated patient outcomes Discuss the emergence of linked donor-recipient databases Critically appraqise the impact of donor age adn gender on

Oct 2
8:00 am | Toronto

Critical Care Canada Forum

The Critical Care Canada Forum 2017 is Canada's national critical care meeting. Held over 4 days, it focuses on clinicians, scientists, and leaders in critical care medicine, and attracts the best speakers worldwide. CCCF consists of superlative plenary talks, thematic sessions and posters, with
This interactive online platform reports national performance data for organ donation and transplantation in Canada. The dashboard consists of nine primary sections presenting data on key aspects of donation and transplantation across the system.

This chapter reviews the testing and treatments that are relevant for mothers and their fetuses/infants during pregnancy and postnatally to reduce the risks of hemolytic disease of the fetus and newborn (HDFN) and of immune thrombocytopenias.